🤯 Have you seen our AI stock pickers’ 2024 results? 84.62%! Grab November’s list now.Pick Stocks with AI

Indian pharma market grows 5.1 pc in September

Published 14-10-2024, 10:25 pm
© Reuters.  Indian pharma market grows 5.1 pc in September
BNPP
-
MOFS
-

New Delhi, Oct 14 (IANS) The Indian pharma market grew 5.1 per cent (year-on-year) in September, led by cardiac, dermal and anti-diabetic therapies, a report showed on Monday.For the 12 months ending in September, the industry grew 7.7 per cent YoY, led by price growth and new launches. However, volume growth was moderate at 0.8 per cent (on-year) last month, according to the report by Motilal Oswal (NS:MOFS) Financial Services Ltd.

Acute therapies grew at a modest rate of 3 per cent YoY while chronic therapies grew at 8 per cent last month.

The share of acute therapies segment in the overall Indian pharma market stood at 61.3 per cent for moving annual total (MAT), with YoY growth of 3 per cent. The chronic therapies segment (38.7 per cent of the total industry) grew 8 per cent, according to the report.

Indian pharma companies held a majority share of 84 per cent in market, while the remaining was held by multinational pharma companies.

According to the report, both MNCs and Indian companies registered single-digit growth (on-quarter) last month.

The industry’s top brand, Augmentin, experienced a decline of 2 per cent YoY to Rs 730 million with a market share of 0.4 per cent last month.

Out of the top 10 brands, Udiliv and Thyronorm clocked 16.5 per cent and 10.2 per cent YoY growth of Rs 569 million and Rs 572 million, respectively, in September.

According to a BNP Paribas (EPA:BNPP) report, they expect firms to continue to cash in on one-off opportunities over FY25-26, readying a product pipeline for launch beyond FY26 would be key.

“Some firms are investing in biosimilars, but we think Indian firms may be late entrants and might not get the traction they expect,” the report mentioned.

--IANS

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.